SAB Biotherapeutics, Inc.

SABS · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.7%

Institutions75.4%

Public / Other

Income Statement

	2025-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$23.90M	$60.88M	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$48.95M	-$28.92M	-$13.39M	–
Operating income as a percentage of revenue.	–	-121.0%	-22.0%	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$13.27M	-$18.74M	-$17.14M	-$8996
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.22	$-0.43	$-0.63	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-0.79	–	$-0.63	–

Balance Sheet

	2025-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$10.50M	$15.05M	$33.21M	–
Everything the company owns that has value — cash, property, inventory, investments, and more.	$172.81M	$50.90M	$79.37M	$322205
All of the company's interest-bearing borrowings, short and long term combined.	$0	$772665	$25013	–
Everything the company owes — debt, unpaid bills, and other obligations.	$21.32M	$19.85M	$40.82M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$151.49M	$31.06M	$38.55M	$16004

Cash Flow Statement

	2025-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$44.78M	-$23.46M	$3.76M	-$10032
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$933156	$2.17M	$10.94M	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$45.71M	-$25.63M	-$7.19M	–

	You	Peer avg
P/E	15.5	–
Revenue Growth	–	-16.1%
ROE	-11.3%	-70.7%

SAB Biotherapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison